Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
February 6, 2023 07:35 AM ESTUpdated 08:16 AM
R&D

Idor­si­a's brain bleed drug flunks PhI­II tri­al, a decade af­ter pre­vi­ous flop

Kyle LaHucik

Senior Reporter

Idor­sia’s long jour­ney with cla­zosen­tan came to an abrupt “un­ex­pect­ed re­sult” Mon­day morn­ing with a Phase III flop.

The Swiss bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Why Re­gen­eron is buy­ing 23andMe

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times